Tigecycline Is Associated with Increased Mortality

The FDA recently alerted clinicians that, in a pooled analysis of clinical trials, the risk for death was higher with tigecycline than with comparator drugs.

Tigecycline is a relatively new antibiotic with a unique spectrum of activity that includes some multidrug-resistant organisms (e.g., methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, extended-spectrum β-lactamase–producing bacteria, Acinetobacter spp.). The drug is FDA approved for treating complicated skin and skin-structure infections, complicated intra-abdominal infections, and community-acquired pneumonia, caused by susceptible pathogens.

On September 1, 2010, the FDA alerted healthcare providers that, in a pooled analysis of 13 clinical trials, tigecycline was significantly associated with increased risk for all-cause mortality (overall adjusted mortality rate, 4% with tigecycline vs. 3% with comparators). …

Author

Lynn L. Estes, PharmD

Disclosures

Editorial boardsMayo Clinic Antimicrobial Therapy Quick Guide

Lynn L. Estes, PharmD

Disclosures

Editorial boardsMayo Clinic Antimicrobial Therapy Quick Guide